AUPH
Aurinia Pharmaceuticals Inc.
$15.78
+0.77%
$2.0B
No data for this timeframe.
Vol
Market Cap$2.0B
Cap SizeMid Cap
Inst. Holders8 funds
Inst. Value$136.4M
Inst. Activity2 buys / 1 sells
Insider Activity6B / 0S
Insider Net $$16.4M
SEC Reports3
Recent Activity
Jun 8, 2026
SEC
Aurinia CEO Kevin Tang made a conviction buy of ~552K shares (~$8.4M in open-market purchases) over three days, with bul
INSIDER-BUY — Impact 6/10
Jun 4, 2026
Insider
Johnson Craig A sold 23,931 shares
Director @ $0.00 ($0.00)
Jun 4, 2026
Insider
Nova Tina Susan sold 23,931 shares
Director @ $0.00 ($0.00)
Jun 4, 2026
Insider
Bailey Jeffrey Allen sold 23,931 shares
Director @ $0.00 ($0.00)
Jun 3, 2026
short_volume
Short Volume: AUPH — 62.1% short (0.4M / 0.7M)
Short: 407,065 | Exempt: 137,396 | TRF Vol: 655,370 | Short Ratio: 62.1% | Off-exchange volume (dark
May 11, 2026
SEC
Aurinia Pharmaceuticals completed its acquisition of Kezar Life Sciences via a tender offer and merger. Shareholders rec
8-K — Impact 5/10
Feb 26, 2026
SEC
Aurinia Pharmaceuticals reported strong financial results for 2025, with total revenue up 20% year-over-year to $283.1 m
8-K — Impact 8/10
Inst.
TWO SIGMA INVESTMENTS, LP — ADD
1,962,742 shares ($31.3M)
Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$17.00 (Dec 2025)
Current $15.78
Low $15.00
Median $17.00
High $21.00
7 analysts
$15.00
$21.00
Analyst Ratings
3Strong Buy
6Buy
4Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Dec 3, 2025 | Leerink Partners | DOWNGRADE | Outperform → Market Perform |
| Nov 7, 2025 | Jefferies | UPGRADE | Hold → Buy |
| Nov 5, 2025 | RBC Capital | DOWNGRADE | Outperform → Sector Perform |
| Aug 1, 2025 | RBC Capital | MAINTAIN | Outperform → Outperform |
| Sep 16, 2024 | Cantor Fitzgerald | REITERATE | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.25 ▲ +12.5% | $0.21 — $0.29 | 55% YoY | 4 |
| Next Q | $0.24 ▲ +15.5% | $0.20 — $0.28 | 5% YoY | 4 |
| Current FY | $0.96 ▲ +15.0% | $0.87 — $1.04 | -54% YoY | 5 |
| Next FY | $1.12 ▲ +33.9% | $0.51 — $1.80 | 16% YoY | 5 |
Latest Reports
BULLISH
INSIDER-BUY
6/10
Aurinia CEO Kevin Tang made a conviction buy of ~552K shares (~$8.4M in open-market purchases) over three days, with bul
Jun 8, 2026
NEUTRAL
8-K
5/10
Aurinia Pharmaceuticals completed its acquisition of Kezar Life Sciences via a tender offer and merger. Shareholders rec
May 11, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $35.4M | ADD |
| TWO SIGMA INVESTMENTS, LP | $31.3M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $25.4M | ADD |
| VANGUARD GROUP INC | $23.1M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $6.9M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Johnson Craig | A | $0.00 |
| Jun 4, 2026 | Nova Tina | A | $0.00 |
| Jun 4, 2026 | Bailey Jeffrey | A | $0.00 |
| Jun 4, 2026 | Goetz Kathleen | A | $0.00 |
| Jun 2, 2026 | TANG KEVIN | J | $16.5K |
8 institutional holders with $136.4M total value (8,552,316 shares) as of 2025-Q4. Top holders: MORGAN, TWO, RENAISSANCE. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 2,216,915 | $35.4M | 25.9% | ADD +43.9% |
| 2 | TWO SIGMA INVESTMENTS, LP | 1,962,742 | $31.3M | 22.9% | ADD +46.4% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 1,590,135 | $25.4M | 18.6% | ADD +25.2% |
| 4 | VANGUARD GROUP INC | 1,449,884 | $23.1M | 17.0% | — |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 432,468 | $6.9M | 5.1% | NEW |
| 6 | BANK OF AMERICA CORP /DE/ | 367,636 | $5.9M | 4.3% | TRIM -29.5% |
| 7 | FMR LLC | 268,302 | $4.3M | 3.1% | ADD +37.5% |
| 8 | WELLS FARGO & COMPANY/MN | 264,234 | $4.2M | 3.1% | DOUBLED +257.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | ADD | 1,341,067 | 1,962,742 | +46.4% | $31.3M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 521,363 | 367,636 | -29.5% | $5.9M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 73,993 | 264,234 | +257.1% | $4.2M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 1,157,800 | 1,449,600 | +25.2% | $16.0M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 161,848 | 1,341,067 | +728.6% | $14.8M | 2025-Q3 |
| FMR LLC | ADD | 158,693 | 218,266 | +37.5% | $2.4M | 2025-Q3 |
| UBS Group AG | TRIM | 325,629 | 198,748 | -39.0% | $2.2M | 2025-Q3 |
| UBS Group AG | ADD | 257,139 | 325,629 | +26.6% | $2.8M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | ADD | 106,888 | 161,848 | +51.4% | $1.4M | 2025-Q2 |
| FMR LLC | ADD | 99,985 | 158,693 | +58.7% | $1.3M | 2025-Q2 |
| MORGAN STANLEY | ADD | 1,645,129 | 2,367,762 | +43.9% | $19.0M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 700,900 | 938,600 | +33.9% | $7.5M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 702,902 | 355,877 | -49.4% | $2.9M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 106,888 | — | $859.4K | 2025-Q1 |
| FMR LLC | TRIM | 179,197 | 99,985 | -44.2% | $803.9K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 1,103,072 | 702,902 | -36.3% | $6.3M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 486,700 | 700,900 | +44.0% | $6.3M | 2024-Q4 |
| UBS Group AG | ADD | 150,699 | 213,273 | +41.5% | $1.9M | 2024-Q4 |
| NORGES BANK | EXIT | 35,532 | 0 | -100.0% | $0.00 | 2024-Q4 |
| MORGAN STANLEY | ADD | 987,876 | 1,470,497 | +48.9% | $10.8M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 744,050 | — | $5.5M | 2024-Q3 |
12 unique insiders with 6 transactions. Net insider value: $16.4M ($16.4M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Johnson Craig A | Director | A | 23,931 | $0.00 | $0.00 |
| Jun 4, 2026 | Nova Tina Susan | Director | A | 23,931 | $0.00 | $0.00 |
| Jun 4, 2026 | Bailey Jeffrey Allen | Director | A | 23,931 | $0.00 | $0.00 |
| Jun 4, 2026 | Goetz Kathleen | Director | A | 23,931 | $0.00 | $0.00 |
| Jun 2, 2026 | TANG KEVIN | Chief Executive Officer | J | 10,000 | $1.65 | $16.5K |
| Jun 2, 2026 | TANG KEVIN | Chief Executive Officer | BUY | 206,005 | $15.28 | $3.1M |
| Jun 1, 2026 | TANG KEVIN | Chief Executive Officer | BUY | 343,521 | $15.28 | $5.2M |
| May 29, 2026 | TANG KEVIN | Chief Executive Officer | BUY | 2,299 | $15.35 | $35.3K |
| May 18, 2026 | Cole Ryan | Chief Operating Officer | A | 116,144 | $0.00 | $0.00 |
| May 18, 2026 | Cole Ryan | Chief Operating Officer | A | 70,230 | $0.00 | $0.00 |
| May 18, 2026 | Hearne Michael S | Chief Financial Officer | A | 116,144 | $0.00 | $0.00 |
| May 18, 2026 | Hearne Michael S | Chief Financial Officer | A | 70,230 | $0.00 | $0.00 |
| May 18, 2026 | Robertson Stephen P. | Chief Legal Officer | A | 115,541 | $0.00 | $0.00 |
| Mar 6, 2026 | Keenan Greg | SVP, Chief Medical Officer | F | 8,069 | $14.32 | $115.5K |
| Mar 3, 2026 | TANG KEVIN | Director | BUY | 184,208 | $14.22 | $2.6M |
| Mar 2, 2026 | Miller Joseph M | Chief Financial Officer | F | 37,511 | $14.21 | $533.0K |
| Mar 2, 2026 | Donley Matthew Maxwell | Chief Operating Officer | F | 40,761 | $14.21 | $579.2K |
| Mar 2, 2026 | Greenleaf Peter | Chief Executive Officer | F | 100,890 | $14.21 | $1.4M |
| Mar 2, 2026 | Robertson Stephen P. | EVP, General Counsel | F | 36,525 | $14.21 | $519.0K |
| Mar 2, 2026 | TANG KEVIN | Director | BUY | 83,561 | $14.33 | $1.2M |
| Feb 27, 2026 | Miller Joseph M | Chief Financial Officer | A | 57,229 | $0.00 | $0.00 |
| Feb 27, 2026 | Miller Joseph M | Chief Financial Officer | A | 95,700 | $0.00 | $0.00 |
| Feb 27, 2026 | Donley Matthew Maxwell | Chief Operating Officer | A | 58,160 | $0.00 | $0.00 |
| Feb 27, 2026 | Greenleaf Peter | Chief Executive Officer | A | 196,403 | $0.00 | $0.00 |
| Feb 27, 2026 | Greenleaf Peter | Chief Executive Officer | A | 328,424 | $0.00 | $0.00 |
| Feb 27, 2026 | Keenan Greg | SVP, Chief Medical Officer | A | 67,870 | $0.00 | $0.00 |
| Feb 27, 2026 | Donley Matthew Maxwell | Chief Operating Officer | A | 97,256 | $0.00 | $0.00 |
| Feb 27, 2026 | Robertson Stephen P. | EVP, General Counsel | A | 59,090 | $0.00 | $0.00 |
| Feb 27, 2026 | Robertson Stephen P. | EVP, General Counsel | A | 98,813 | $0.00 | $0.00 |
| Feb 27, 2026 | Keenan Greg | SVP, Chief Medical Officer | A | 40,586 | $0.00 | $0.00 |
| Feb 27, 2026 | TANG KEVIN | Director | BUY | 300,000 | $13.90 | $4.2M |
| Feb 20, 2026 | Donley Matthew Maxwell | Chief Operating Officer | F | 32,901 | $14.40 | $473.8K |
| Feb 20, 2026 | Greenleaf Peter | Chief Executive Officer | F | 100,171 | $14.40 | $1.4M |
| Feb 20, 2026 | Miller Joseph M | Chief Financial Officer | F | 32,424 | $14.40 | $466.9K |
| Feb 20, 2026 | Robertson Stephen P. | EVP, General Counsel | F | 34,638 | $14.40 | $498.8K |
| Feb 2, 2026 | Keenan Greg | SVP, Chief Medical Officer | F | 11,552 | $14.53 | $167.9K |
3 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 6.3/10.
BULLISH
INSIDER-BUY
6/10
Aurinia CEO Kevin Tang made a conviction buy of ~552K shares (~$8.4M in open-market purchases) over
Jun 8, 2026
NEUTRAL
8-K
5/10
Aurinia Pharmaceuticals completed its acquisition of Kezar Life Sciences via a tender offer and merg
May 11, 2026
BULLISH
8-K
8/10
Aurinia Pharmaceuticals reported strong financial results for 2025, with total revenue up 20% year-o
Feb 26, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Dec 2025): 69% buy across 13 analysts — 3 strong buy, 6 buy, 4 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$17.00 mean target (Dec 2025)
$15.00 Low
$21.00 High
| Metric | Value |
|---|---|
| Current Price | $15.78 |
| Target Low | $15.00 |
| Target Mean | $17.00 |
| Target Median | $17.00 |
| Target High | $21.00 |
| # Analysts | 7 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.25 | $0.21 | $0.29 | 54.7% | +12.5% | 1↑ 0↓ | $0.1B | 14.6% | 4 |
| Next Q 2026-09-30 |
$0.24 | $0.20 | $0.28 | 5.4% | +15.5% | 1↑ 0↓ | $0.1B | 11.9% | 4 |
| Current FY 2026-12-31 |
$0.96 | $0.87 | $1.04 | -53.6% | +15.0% | 1↑ 0↓ | $0.3B | 14.6% | 5 |
| Next FY 2027-12-31 |
$1.12 | $0.51 | $1.80 | 16.5% | +33.9% | 1↑ 0↓ | $0.4B | 19.3% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.247 | |
| 7d ago | $0.203 | +0.044 |
| 30d ago | $0.220 | +0.027 |
| 60d ago | $0.220 | +0.027 |
| 90d ago | $0.180 | +0.068 |
13 analyst firms have rated this stock: 2 upgrades, 5 downgrades, 6 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Dec 3, 2025 | Leerink Partners | DOWNGRADE | Outperform | Market Perform |
| Nov 7, 2025 | Jefferies | UPGRADE | Hold | Buy |
| Nov 5, 2025 | RBC Capital | DOWNGRADE | Outperform | Sector Perform |
| Aug 1, 2025 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Sep 16, 2024 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Sep 9, 2024 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Sep 6, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 1, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 23, 2024 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Feb 22, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 16, 2024 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Sep 22, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 7, 2023 | HC Wainwright& Co. | MAINTAIN | Buy | Buy |
| Jul 6, 2023 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| May 3, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Feb 23, 2023 | RBC Capital | REITERATE | — | Outperform |
| Jan 4, 2023 | RBC Capital | MAINTAIN | — | Outperform |
| Nov 7, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Nov 4, 2022 | RBC Capital | MAINTAIN | — | Outperform |
| Nov 4, 2022 | Oppenheimer | DOWNGRADE | Outperform | Perform |
| Nov 4, 2022 | SVB Leerink | MAINTAIN | — | Outperform |
| Aug 9, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Aug 8, 2022 | Oppenheimer | MAINTAIN | — | Outperform |
| May 5, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Apr 28, 2022 | RBC Capital | MAINTAIN | — | Outperform |
| Mar 8, 2022 | SVB Leerink | MAINTAIN | — | Outperform |
| Mar 1, 2022 | RBC Capital | MAINTAIN | — | Outperform |
| Feb 23, 2022 | RBC Capital | MAINTAIN | — | Outperform |
| Dec 10, 2021 | Oppenheimer | UPGRADE | Perform | Outperform |
| Nov 4, 2021 | Oppenheimer | MAINTAIN | — | Perform |
| Nov 4, 2021 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Nov 4, 2021 | SVB Leerink | MAINTAIN | — | Outperform |
| Oct 28, 2021 | Oppenheimer | DOWNGRADE | Outperform | Perform |
| Oct 26, 2021 | RBC Capital | MAINTAIN | — | Outperform |
| Jan 27, 2021 | SVB Leerink | MAINTAIN | — | Outperform |
| Jan 25, 2021 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Nov 3, 2020 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Aug 12, 2020 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Jul 22, 2020 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Mar 6, 2020 | Cantor Fitzgerald | MAINTAIN | — | Overweight |
| Dec 16, 2019 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Sep 10, 2019 | Oppenheimer | INITIATE | — | Outperform |
| Mar 20, 2019 | Raymond James | MAINTAIN | — | Outperform |
| Feb 8, 2018 | RBC Capital | INITIATE | — | Outperform |
| Oct 23, 2017 | Leerink Swann | MAINTAIN | — | Outperform |
| Oct 6, 2017 | Seaport Global | INITIATE | — | Buy |
| Sep 13, 2017 | Canaccord Genuity | DOWNGRADE | Buy | Speculative Buy |
| Apr 10, 2017 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Nov 1, 2016 | Mackie Research | INITIATE | — | Speculative Buy |
| Jun 30, 2016 | HC Wainwright & Co. | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% | |
| May 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% | |
| Apr 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% | |
| Mar 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% | |
| Feb 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% | |
| Jan 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
short_volume
Short Volume: AUPH — 62.1% short (0.4M / 0.7M)
Short: 407,065 | Exempt: 137,396 | TRF Vol: 655,370 | Short Ratio: 62.1% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: AUPH — 58.1% short (0.3M / 0.5M)
Short: 295,906 | Exempt: 98,672 | TRF Vol: 509,206 | Short Ratio: 58.1% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_interest
FTD: AUPH — 122,310 shares ($2.0M) failed to deliver
Settlement: 20260513, Price: $15.99, FTD Value: $1,955,736.9, AURINIA PHARMACEUTICALS INC OR
May 11, 2026
earnings_calendar
AUPH Q1 2026 Earnings Scheduled — 2026-05-11
May 7, 2026
short_volume
Short Volume: AUPH — 55.5% short (0.6M / 1.2M)
Short: 648,243 | Exempt: 37,687 | TRF Vol: 1,167,282 | Short Ratio: 55.5% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
earnings_calendar
AUPH Q1 2026 Earnings Scheduled — 2026-04-30
Apr 28, 2026
short_interest
FTD: AUPH — 71,547 shares ($1.2M) failed to deliver
Settlement: 20260428, Price: $16.37, FTD Value: $1,171,224.39, AURINIA PHARMACEUTICALS INC OR
Mar 23, 2026
short_volume
Short Volume: AUPH — 63.9% short (0.6M / 1.0M)
Short: 647,983 | Exempt: 1,910 | TRF Vol: 1,013,833 | Short Ratio: 63.9% | Off-exchange volume (dark pool + OTC)
Feb 26, 2026
earnings_calendar
AUPH Q4 2025 Earnings After Market Close — 2026-02-26
Feb 24, 2026
Clinical Trial
Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis
Phase Phase 3 — TERMINATED
Feb 24, 2026
Clinical Trial
Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis
Phase Phase 3 — TERMINATED
Feb 9, 2026
short_interest
FTD: AUPH — 78,346 shares ($1.1M) failed to deliver
Settlement: 20260209, Price: $14.44, FTD Value: $1,131,316.24, AURINIA PHARMACEUTICALS INC OR